DelveInsight’s “Nonalcoholic Steatohepatitis (NASH) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Nonalcoholic Steatohepatitis (NASH), historical and forecasted epidemiology as well as the Nonalcoholic Steatohepatitis (NASH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight launched a new report on Nonalcoholic Steatohepatitis (NASH) – Market Insights, Epidemiology, and Market Forecast-2030.
The key facts of the report:1. According to DelveInsight, increase in obesity, diabetes population will significantly increase the prevalent cases of NAFLD with the CAGR of 1.02% for the study period i.e. 2016-2027 in the 7MM.2. Of all the prevalent cases of NAFLD in the 7MM, approximately 19% of the population fulfilled the criteria for NASH.3. These cases are expected to increase throughout the study period [2016-2027], reaching nearly 47 million cases in 2027.
Key benefits of the report:1. 11 Years Forecast2. 7MM Coverage 3. Nonalcoholic Steatohepatitis (NASH) Epidemiology Segmentation4. Key Cross Competition 5. Highly Analyzed Market6. Drugs Uptake
Request for sample pages: https://www.delveinsight.com/sample-request/nonalcoholic-steatohepatitis-nash-market
Nonalcoholic Steatohepatitis (NASH) is the progressive form of liver injury that carries a risk of progressive fibrosis, cirrhosis, and end-stage liver disease. It is an advanced form of nonalcoholic fatty liver disease (NAFLD), caused by the buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver. Scarring of the liver is a potentially life-threatening condition called cirrhosis.
Key pharma players involved:1. Genfit2. Intercept Pharmaceuticals3. Gilead Sciences4. Tobira Therapeutics5. Galmed Pharmaceuticals6. Bristol-Myers Squibb7. Cirius Therapeutics8. Conatus Pharmaceuticalsand many others
Emerging therapies:1. Obeticholic acid (OCA)2. Selonsertib3. Emricasan4. GR-MD-025. IMM-124Eand many others
Download free sample pages: https://www.delveinsight.com/sample-request/nonalcoholic-steatohepatitis-nash-market
Table of contents:1. Key Insights2. Executive Summary of Nonalcoholic Steatohepatitis (NASH)3. Competitive Intelligence Analysis for Nonalcoholic Steatohepatitis (NASH)4. Nonalcoholic Steatohepatitis (NASH): Market Overview at a Glance5. Nonalcoholic Steatohepatitis (NASH): Disease Background and Overview6. Patient Journey7. Nonalcoholic Steatohepatitis (NASH) Epidemiology and Patient Population8. Treatment Algorithm, Current Treatment, and Medical Practices9. Unmet Needs10. Key Endpoints of Nonalcoholic Steatohepatitis (NASH) Treatment11. Marketed Products12. Emerging Therapies13. Nonalcoholic Steatohepatitis (NASH): Seven Major Market Analysis14. Attribute analysis15. 7MM: Market Outlook16. Access and Reimbursement Overview of Nonalcoholic Steatohepatitis (NASH)17. KOL Views18. Market Drivers19. Market Barriers20. Appendix21. DelveInsight Capabilities22. Disclaimer23. About DelveInsight
Related reports:
Nonalcoholic Steatohepatitis (NASH) – Epidemiology Forecast to 2030
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/